首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1105179篇
  免费   75247篇
  国内免费   1476篇
耳鼻咽喉   15635篇
儿科学   35726篇
妇产科学   29518篇
基础医学   158604篇
口腔科学   30339篇
临床医学   97654篇
内科学   209962篇
皮肤病学   25116篇
神经病学   84639篇
特种医学   44505篇
外国民族医学   217篇
外科学   167661篇
综合类   21907篇
现状与发展   1篇
一般理论   270篇
预防医学   76382篇
眼科学   24912篇
药学   87931篇
  7篇
中国医学   2831篇
肿瘤学   68085篇
  2021年   8088篇
  2019年   8209篇
  2018年   11874篇
  2017年   9391篇
  2016年   10748篇
  2015年   12005篇
  2014年   16156篇
  2013年   23398篇
  2012年   32340篇
  2011年   34198篇
  2010年   19940篇
  2009年   18818篇
  2008年   31637篇
  2007年   33888篇
  2006年   34400篇
  2005年   32773篇
  2004年   31268篇
  2003年   30100篇
  2002年   28904篇
  2001年   60816篇
  2000年   62287篇
  1999年   51660篇
  1998年   12873篇
  1997年   11373篇
  1996年   11309篇
  1995年   10586篇
  1994年   9581篇
  1993年   9096篇
  1992年   38201篇
  1991年   36704篇
  1990年   36175篇
  1989年   34661篇
  1988年   31193篇
  1987年   30352篇
  1986年   28582篇
  1985年   26778篇
  1984年   19454篇
  1983年   16326篇
  1982年   8996篇
  1979年   17271篇
  1978年   11588篇
  1977年   10393篇
  1976年   8993篇
  1975年   10231篇
  1974年   11850篇
  1973年   11435篇
  1972年   10907篇
  1971年   10212篇
  1970年   9380篇
  1969年   9053篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Quality of Life Research - The COVID-19 pandemic might add to the stressors experienced by people living with rheumatic diseases. This study aimed to examine rheumatic patients’ functional...  相似文献   
3.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
4.
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation.  相似文献   
5.
6.
7.
8.
9.
Inflammatory bowel disease (IBD) is a chronic disease that requires chronic treatment throughout the evolution of the disease, with a complex physiopathology that entails great challenges for the development of new and specific treatments for ulcerative colitis and Crohn´s disease. The anti-tumor necrosis factor alpha therapy has impacted the clinical course of IBD in those patients who do not respond to conventional treatment, so there is a need to develop new therapies and markers of treatment response. Various pathways involved in the development of the disease are known and the new therapies have focused on blocking the inflammatory process at the gastrointestinal level by oral, intravenous, subcutaneous, and topical route. All these new therapies can lead to more personalized treatments with higher success rates and fewer relapses. These treatments have not only focused on clinical remission, but also on achieving macroscopic changes at the endoscopic level and microscopic changes by achieving mucosal healing. These treatments are mainly based on modifying signaling pathways, by blocking receptors or ligands, reducing cell migration and maintaining the integrity of the epithelial barrier. Therefore, this review presents the efficacy and safety of the new treatments that are currently under study and the advances that have been made in this area in recent years.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号